Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature |
| |
Authors: | Yomtovian Roslyn Niklinski Waldemar Silver Bernard Sarode Ravindra Tsai Han-Mou |
| |
Institution: | Department of Pathology, The University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH, USA. |
| |
Abstract: | Deficiency of von Willebrand factor (VWF) cleaving protease ADAMTS13 has been demonstrated to be the proximate cause of a subset of thrombotic microangiopathic haemolytic anaemias (MAHA) typical for thrombotic thrombocytopenic purpura (TTP). ADAMTS13 gene mutations cause the hereditary form; acquired deficiency has been attributed to presence of an autoantibody, which may represent a specific subset of MAHA best termed 'autoimmune thrombotic thrombocytopenic purpura'. We describe a patient with relapsing TTP because of ADAMTS13 inhibitors, who failed to achieve sustained remission despite therapies with plasma exchange, steroids, vincristine, staphylococcal protein A and splenectomy. The ADAMTS13 inhibitor titre remained elevated and clinical stability was only maintained by plasma exchange every 2-3 d over a period of 268 d. The patient then received rituximab therapy (eight doses of 375 mg/m2 weekly), during which she required five plasma exchanges in the first 10 d, two exchanges in the next 3 weeks, and none thereafter for 450 d and ongoing. The ADAMTS13 inhibitor titre decreased and enzyme activity increased. We compared this case with that of seven previously reported TTP cases also treated with rituximab; experience suggests that rituximab therapy deserves further investigation for patients with either refractory or relapsing TTP caused by ADAMTS13 inhibitors. |
| |
Keywords: | thrombotic thrombocytopenic purpura rituximab plasma exchange |
本文献已被 PubMed 等数据库收录! |
|